PHARMA DISCOUNT: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMA DISCOUNT
Largest movements
- Cash -€3,133
down €3,133 (-77.1%), from €4,063 to €929
mainly Net result for the year (-€6,696) and Deferred charges and accrued income (-€165)
- Tangible fixed assets -€2,661
down €2,661 (-39.7%), from €6,701 to €4,040
of which Furniture and vehicles: -€2,511
- Deferred charges and accrued income +€165
up €165 (+127.3%), from €129 to €294
- Profit (loss) carried forward -€6,696
down €6,696 (-28.1%), from -€23,831 to -€30,526
- Other debts +€1,066
up €1,066 (+3.3%), from €32,010 to €33,076
- Gross operating margin -€6,318
down €6,318, from €2,332 to -€3,986
- Financial charges +€44
up €44 (+966.7%), from €5 to €48
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €14,899 | €9,269 | -€5,630 | -37.8% |
| Fixed assets | 21/28 | €6,701 | €4,040 | -€2,661 | -39.7% |
| Tangible fixed assets | 22/27 | €6,701 | €4,040 | -€2,661 | -39.7% |
| Furniture and vehicles | 24 | €5,512 | €3,001 | -€2,511 | -45.6% |
| Other tangible fixed assets | 26 | €1,189 | €1,039 | -€150 | -12.6% |
| Financial fixed assets | 28 | €0 | - | = | |
| Current assets | 29/58 | €8,199 | €5,230 | -€2,969 | -36.2% |
| Amounts receivable within one year | 40/41 | €4,006 | €4,006 | = | 0.0% |
| Other amounts receivable | 41 | €4,006 | €4,006 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €4,063 | €929 | -€3,133 | -77.1% |
| Deferred charges and accrued income | 490/1 | €129 | €294 | +€165 | +127.3% |
| Total equity and liabilities | 10/49 | €14,899 | €9,269 | -€5,630 | -37.8% |
| Equity | 10/15 | -€17,831 | -€24,526 | -€6,696 | -37.6% |
| Contributions | 10/11 | €6,000 | €6,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€23,831 | -€30,526 | -€6,696 | -28.1% |
| Amounts payable | 17/49 | €32,730 | €33,796 | +€1,066 | +3.3% |
| Amounts payable after more than one year | 17 | €720 | €720 | = | 0.0% |
| Other amounts payable | 178/9 | €720 | €720 | = | 0.0% |
| Amounts payable within one year | 42/48 | €32,010 | €33,076 | +€1,066 | +3.3% |
| Trade debts | 44 | €0 | - | = | |
| Suppliers | 440/4 | €0 | - | = | |
| Other amounts payable | 47/48 | €32,010 | €33,076 | +€1,066 | +3.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,661 | €2,661 | = | 0.0% |
| Other operating charges | 640/8 | €0 | - | = | |
| Gross operating margin | 9900 | €2,332 | -€3,986 | -€6,318 | |
| Operating profit (loss) | 9901 | -€330 | -€6,648 | -€6,318 | -1916.3% |
| Financial income | 75/76B | €21 | €0 | -€21 | -100.0% |
| Recurring financial income | 75 | €21 | €0 | -€21 | -100.0% |
| Financial charges | 65/66B | €5 | €48 | +€44 | +966.7% |
| Recurring financial charges | 65 | €5 | €48 | +€44 | +966.7% |
| Profit (loss) for the period before taxes | 9903 | -€313 | -€6,696 | -€6,383 | -2039.2% |
| Profit (loss) for the period | 9904 | -€313 | -€6,696 | -€6,383 | -2039.2% |
| Profit (loss) for the period to be appropriated | 9905 | -€313 | -€6,696 | -€6,383 | -2039.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 7 October 2026 via checked.be.